Illumina (NASDAQ:ILMN) Director Scott Gottlieb Buys 200 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Scott Gottlieb bought 200 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was purchased at an average cost of $117.81 per share, with a total value of $23,562.00. Following the transaction, the director directly owned 12,723 shares in the company, valued at approximately $1,498,896.63. This represents a 1.60% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Illumina Stock Down 2.5%

Shares of NASDAQ ILMN traded down $2.94 during mid-day trading on Wednesday, hitting $116.38. 2,032,582 shares of the stock traded hands, compared to its average volume of 2,240,057. The company has a market cap of $17.78 billion, a price-to-earnings ratio of 21.35, a PEG ratio of 2.24 and a beta of 1.45. The stock has a fifty day moving average price of $138.04 and a 200-day moving average price of $116.48. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter last year, the firm posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. Robert W. Baird set a $137.00 target price on shares of Illumina in a research note on Friday, February 6th. Stifel Nicolaus lifted their price objective on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Finally, Evercore ISI set a $150.00 price objective on shares of Illumina in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $129.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. MassMutual Private Wealth & Trust FSB increased its stake in shares of Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares in the last quarter. Assetmark Inc. raised its holdings in Illumina by 10.2% during the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 96 shares during the period. Envestnet Portfolio Solutions Inc. lifted its position in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its position in shares of Illumina by 4.2% during the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after purchasing an additional 99 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.